Hamideh Parhiz, Pharm.D., Ph.D.
Assistant Professor of Systems Pharmacology and Translational Therapeutics

- Co-director of targeting core, Penn Institute for RNA Innovation, University of Pennsylvania
Department: Systems Pharmacology and Translational Therapeutics
Graduate Group Affiliations
Contact Information
421 Curie Boulevard
Biomedical Research Building II/III Room 1256
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
Email: hamideh.parhiz@pennmedicine.upenn.edu
I3H Keywords
- Array
Education
-
PharmD (Pharmacy)
Mashhad University of Medical Sciences, Iran, 2005 -
PhD (Pharmaceutical Biotechnology)
Mashhad University of Medical Sciences, Iran, 2011
Post-Graduate Training
-
Postdoctoral Research Fellow
Center for Translational Targeted Therapeutics and Nanomedicine, University of Pennsylvania, Philadelphia, PA, 2016 - 2018
Certifications
- FPGEC certificate, The National Association of Boards of Pharmacy , 2017
Description of Research Expertise
Nucleic acid-based therapeutics
Nano-engineering
Targeted delivery of nanomedicine
mRNA therapeutics
Autoimmunity
Cancer Immunology and Immunotherapy
Research Interests:
Our lab develops novel nucleic acid delivery systems, including a new generation of targeted lipid nanoparticle (tLNP), for in vivo cellular reprogramming. We leverage these systems for mRNA-based therapeutics in a variety of non-vaccine applications such as inherited diseases, acquired or congenital hematopoietic conditions, cancers, fibrosis, and acute inflammatory conditions. We also investigate the mechanisms underlying the enhancement of delivery systems such as the ones related to more favorable pharmacokinetic profile, to apply those principles in designing more effective gene and mRNA therapeutics. Currently, the targeted LNP-mRNA platform we design serves as the foundation for ongoing academic programs and industrial product developments.
Selected Publications
- Shuvaev VV, Tam YK, Lee BW, Myerson JW, Herbst A, Kiseleva RY, Glassman PM, Parhiz H, Alameh MG, Pardi N, Muramatsu H, Shuvaeva TI, Arguiri E, Marcos-Contreras OA, Hood ED, Brysgel TV, Nong J, Papp TE, Eaton DM, Riley R, Palanki R, Musunuru K, Brenner JS, Mitchell MJ, Ferrari VA, Mui BL, Semple SC, Weppler SA, Atluri P, Margulies KB, Weissman D, Muzykantov VR. : Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo Proc Natl Acad Sci U S A 122 : e2409266122, Jul 2025
- Papp TE, Zeng J, Shahnawaz H, Akyianu A, Breda L, Yadegari A, Steward J, Shi R, Li Q, Mui BL, Tam YK, Weissman D, Rivella S, Shuvaev V, Muzykantov VR, Parhiz H. : CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery Mol Ther 33 : 3195-3208, Jul 2025
- Nakamichi S, von Muhlinen N, Yamada L, Melamed JR, Papp TE, Parhiz H, Weissman D, Horikawa I, Harris CC. : SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer bioRxiv May 2025
- Reyes-Esteves S, Majumder A, Marzolini N, Zamora M, Wang Y, Espy C, Papp TE, Akyianu A, Nong J, Messe L, Omo-Lamai S, Parhiz H, Myerson J, Marcos-Contreras O, Brenner J. : Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage Res Sq Apr 2025
- Yashaswini CN, Cogliati B, Qin T, To T, Williamson T, Papp TE, Li K, Rasul R, Chen L, Lightstone A, Aghajanian H, Parhiz H, Wang S, Rurik JG, Epstein JA, Friedman SL. : In vivo anti-FAP CAR T therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis bioRxiv Feb 2025
- Kimura K, Aicher A, Niemeyer E, Areesawangkit P, Tilsed C, Fong KP, Papp TE, Albelda SM, Parhiz H, Predina JD. : In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo Vaccines (Basel) 13 : 178, Feb 2025
- Castruccio Castracani C, Breda L, Papp TE, Guerra A, Radaelli E, Assenmacher CA, Finesso G, Mui BL, Tam YK, Fontana S, Riganti C, Fiorito V, Petrillo S, Tolosano E, Parhiz H, Rivella S. : An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA Blood 145 : 98-113, Jan 2025
- Omo-Lamai S, Wang Y, Patel MN, Milosavljevic A, Zuschlag D, Poddar S, Wu J, Wang L, Dong F, Espy C, Majumder A, Essien EO, Shen M, Channer B, Papp TE, Tobin M, Maheshwari R, Jeong S, Patel S, Shah A, Murali S, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Discher D, Gaskill PJ, Tsourkas A, Muzykantov VR, Brodsky I, Shin S, Whitehead KA, Parhiz H, Katzen J, Miner JJ, Trauner D, Brenner JS. : Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape Nat Nanotechnol 2025
- Chappell ME, Breda L, Tricoli L, Guerra A, Jarocha D, Castruccio Castracani C, Papp TE, Tanaka N, Hamilton N, Triebwasser MP, Ghiaccio V, Fedorky MT, Gollomp KL, Bochenek V, Roche AM, Everett JK, Cook EJ, Bushman FD, Teawtrakul N, Glentis S, Kattamis A, Mui BL, Tam YK, Weissman D, Abdulmalik O, Parhiz H, Rivella S. : Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy Blood 144 : 1633-1645, Oct 2024
- Mukalel AJ, Hamilton AG, Billingsley MM, Li J, Thatte AS, Han X, Safford HC, Padilla MS, Papp T, Parhiz H, Weissman D, Mitchell MJ. : Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering Adv Funct Mater 34 : 2312038, Jul 2024